Alkermes Invests In Novel CNS Targets With Rodin Acquisition
Executive Summary
Rodin is developing HDAC CoREST complex inhibitors for neurological conditions, with a lead candidate having completed Phase I testing. Alkermes will pay $100m upfront.You may also be interested in...
Deal Watch: Molecular Templates Aligns With Vertex On Optimizing Stem Cell Candidates
Alliance with Molecular Templates may help advance efforts under Vertex’s existing collaboration with CRISPR Therapeutics. Dragonfly’s latest partner for its TriNKET platform is AbbVie.
Biogen Vumerity Receives Full US Approval, But GI Comparison With Tecfidera Must Wait
Label offers little differentiation from Tecfidera, but head-to-head trial with custom-designed patient-reported outcome could make case for gastrointestinal tolerability advantage.
Alkermes Restructures, Prioritizing CNS And Oncology And Cutting 160 Employees
The reorganization, which is expected to save $150m, will cement the company's transition from a drug delivery specialist to a drug developer, CEO Richard Pops said.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
